Cell-mediated Immunity to Toxoplasma Gondii: Initiation, Regulation and Effector Function
Overview
Affiliations
Cell-mediated immune responses are essential for host control of intracellular infections. Toxoplasma gondii is a protozoan parasite that infects multiple vertebrate species and invades multiple cell types. Upon initial encounter with the immune system, the parasite rapidly induces production of the type-1 promoting cytokine IL-12 most likely from a subpopulation of dendritic cells. NK and T cells are then activated and triggered to synthesize IFN-gamma, the major mediator of host resistance during the acute and chronic phases of infection. During the acute phase, a concomitant IL-10 response dampens the systemic type-1 cytokine production and prevents lethal immunopathology. Cytokine (IFN-gamma und TNF-alpha) rather than cytotoxicity-based effector functions are more critical for protective immunity both during the acute and chronic phases of T. gondii infection. Both hemopoietic and non-hemopoietic cellular elements act as IFN-gamma and TNF-dependent effectors of host resistance. Type II iNOS-derived nitric oxide (NO) is required mainly for hemopoietic cell-derived effector cell activity in the central nervous system (CNS) during the chronic phase of infection. Nevertheless, in both the acute and chronic stages, IFN-gamma-dependent but iNOS-independent mechanism(s) play a major function in parasite control and their identification remains an important challenge for this field.
IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review.
Dagher J, Ringuet J SAGE Open Med Case Rep. 2025; 13:2050313X251320196.
PMID: 39967610 PMC: 11833812. DOI: 10.1177/2050313X251320196.
Hoover E, Schneider C, Crouzet C, Lima T, Velez D, Tran C J Neuroinflammation. 2025; 22(1):3.
PMID: 39780244 PMC: 11708167. DOI: 10.1186/s12974-024-03330-1.
Early immune response to lineage III isolates of different virulence phenotype.
Uzelac A, Klun I, Djurkovic-Djakovic O Front Cell Infect Microbiol. 2024; 14:1414067.
PMID: 38912206 PMC: 11190176. DOI: 10.3389/fcimb.2024.1414067.
New advances in immune mechanism and treatment during ocular toxoplasmosis.
Chen Z, Cheng S, Chen X, Zhang Z, Du Y Front Immunol. 2024; 15:1403025.
PMID: 38799473 PMC: 11116678. DOI: 10.3389/fimmu.2024.1403025.
Ewald S, Nasuhidehnavi A, Feng T, Lesani M, McCall L Microbiol Mol Biol Rev. 2024; 88(1):e0016422.
PMID: 38299836 PMC: 10966954. DOI: 10.1128/mmbr.00164-22.